without concomitant platinum-based chemotherapy) not amenable to salvage surgery or radiation therapy were eligible. There were no restrictions on prior platinumbased chemotherapy. Upon review of patient's files, 60 cases were properly followed and documented. the treatment schedule was as follows:
Arm I: Methotrexate (MTX) was injected weekly as an intravenous push at 40mg/m 2 .
Arm II: Cisplatin/5-Fluorouracil (PF) was administered as cisplatin (at a dose of 100 mg/m 2 as a 2-hour intravenous infusion on day 1) and a continuous infusion of fluorouracil (at a dose of 1000 mg/m 2 per day for 4 days) every 3 weeks.
statistical Methods:
Overall survival was calculated from treatment initiation to death or last follow-up. PFS was calculated from treatment initiation to disease progression or last follow-up, Response rate by RECIST criteria 6 and toxicity profile by the National Cancer Institute Common Toxicity Criteria (NCI CTC), version 3.0.7
Data were then analyzed statistically using SPSS Statistical package version 17 with calculation of mean, median and confidence interval. The Kaplan-Meier method was used for the calculation of the overall survival and progression free survival.
results
Between March 2007 and November 2011, sixty eligible patients were recruited. 32 patients received single agent chemotherapy methotrexate and 28 patients received combination chemotherapy Cisplatin/5-Fluorouracil. A total of 207 weekly MTX injections were recorded with a median of 5 injections and a range of two to sixteen. For PF regimen a total of 91 cycles recorded with a median of 3 cycles and a range of one to six per patient. Pretreatment characteristics of the 60 eligible patients are listed in Table ( 1) . Two patients did not receive radiotherapy in PF regimen because both were laryngeal carcinoma who underwent total laryngectomy with no indication for adjuvant radiotherapy and then presented later on with distant metastases. We have to mention that 59.37% of patients receiving MTX have a performance status of 2 while 64.28% of PF have performance status of 0-1.
Efficacy:
Tumor response was assessed in all sixty patients as seen in Table ( 2). Overall response rates were 12.5%, and 32.14% in the methotrexate and Cisplatin/5-FU arm, respectively. PF regimen had significant superior median progression free survival than MTX 3.25 months (95% 2.32 to 4.17) vs 1.5 months (95% 1.16 to 1.83) respectively (P= 0.01). There was no significant difference in overall survival between treatment arms. Median survival in patients receiving MTX and PF was 5 months (95% 4.17 to 5.83) and 6 months (95% 5.03 to 6.96) respectively (P= 0.08). Progression free survival and overall survival are illustrated in Figure (1) and (2) . Three patients in PF regimen with loco-regional recurrence underwent surgery for residual disease.
safety:
Eight treatment related mortality occurred, 2 in arm I and 6 in arm II during treatment: five from infection, two from hemorrhage and one from cardiac cause. Hematological toxicity was significantly more in PF regimen (P= 0.01). Therefore, a dose reduction in 23 patients (82.14%) of PF regimen was monitored. Febrile neutropenia was recorded in 13 patients (46.42%) with 5 deaths encountered. Non hematological toxicity included vomiting and stomatitis mainly, creatinine elevation was significantly in PF regimen while transaminases elevation was significantly in MTX regimen. Grade 3 and 4 adverse effects are illustrated in Table ( 3). 
dIscussIon
Treatment of patients with R/M SCCHN is a hard task. In spite of all available treatment lines the prognosis is poor. After salvage surgery and radiation therapy and in the majority of patients, chemotherapy should be used with a palliative aim.1,2 In our country with limited resources, we prefer to use cost effective therapy in palliative settings. In this study we highlighted outcomes of our unit guideline as a center during the last 4 years.
Single agent methotrexate is considered to be the historical standard and has been most frequently investigated as a weekly intravenous regimen. It is a cost effective medication, easy to administer not requiring hospital admission and exhaustion of resources. A weekly dose of 40-60mg/m 2 of methotrexate were considered standard therapy with variable response rate recorded between 3.9-25%. Overall survival reported with MTX was around 6 months [8] [9] [10] [11] . In our study, we witnessed 12.5% response rate and 5 months median overall survival which is comparable with published data.
During the last decade, Cisplatin/infusional 5-FU (PF) regimen gradually became as the most popular combination chemotherapy regimen in patients with R/M SCCHN in view of its higher response and superior PFS. Non-randomized trials indicated a better outcome than what was observed with single-agent treatment, at least with respect to OR rates including CR/PR rates. In a number of randomized phase III trials performed in the 1990s, PF regimen was shown to be superior to single-agent regimens, in terms of response rates but not in statistically significant survival advantage, and this gain in response rates was obtained at the cost of more toxicity 12, 13 . In a phase III trial, 277 patients were randomized to receive PF, carboplatin-5-FU (CF) or standard dose MTX. PF had significantly higher response rate than MTX (P= < 0.001), but the comparison of PF with MTX was of only borderline significance (P= 0.05). And again, median survivals were similar for all three treatment groups 8 . Which is comparable to our results where PF had significant more response rate, progression free survival than MTX. However, there was no statistically survival advantage.
Toxicity of PF regimen is a major concern, we witnessed six (21.42%) treatment related mortality during the first two cycles in contrast with data reported in Intergroup Trial of the Eastern Cooperative Oncology Group where 6.7% of patients had toxic death from treatment 14 . So, we have to give this toxic regimen to patients with good performance status (0-1) with some precautions like 25% dose reduction for the initial cycles, careful follow-up, and administration of prophylactic growth factors support especially in elderly patients. Another important issue is the renal toxicity commonly encountered with PF regimen, we noticed two patients with grade 3 serum creatinine elevation. In such situation, increasing hydration carefully especially with patients with borderline cardiac function is recommended. Otherwise, substitution of Cisplatin with carboplatin especially when creatinine clearance drops to ≤ 50 mL/min.
Although taxanes have considerable activity in R/M SCCHN, no randomized studies performed in the palliative setting have demonstrated a significant improvement in overall survival 10, 15 . In a phase III trial 218 patients with R/M-SCCHN were randomized to either PF or cisplatin-paclitaxel. There was no significant difference in overall survival, response rate or toxicity profile 14 .
The addition of the monoclonal antibody cetuximab to platinum and Fluorouracil appear to be the standard of care for patients with good performance status. In a phase III trial, the addition of cetuximab was shown to improve median survival from 7.4 to 10.1 months and median progression-free survival from 3.3 to 5.6 months with significant acceptable toxicities 5 . however, availability of cetuximab in our governmental center especially for a palliative treatment of patients with R/M SCCHN is quiet problematic.
conclusIon
In conclusion, the outcome of patients with R/M SCCHN is still dismal. We documented that combination chemotherapy PF had significant superior response rate, progression free survival and non significant longer overall survival than single agent MTX. The choice of chemotherapy depends on disease symptoms and performance status. If rapid improvement in symptoms is desired with good performance status, combination therapy is preferable; however, if non-symptomatic disease in a poor performance patient, use single agent might be more valuable. Novel non-toxic agents or approaches for the treatment of R/M-SCCHN are eagerly awaited.
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